论文部分内容阅读
目的:探讨晚期胃癌合并腹腔积液通过循环腹腔热灌注化疗的不良反应。方法:研究我院2014年10月至2015年10月期间收治的晚期胃癌合并腹腔积液患者,分为对照组和观察组各40例,其中对照组运用常规化疗,观察组运用循环腹腔热灌注化疗,分析两组患者治疗效果和不良反应情况。结果:治疗有效率上,观察组为80%,对照组为57.5%,两组差异具有统计学意义,P<0.05;不良反应发生率上,观察组为45%,对照组为67.5%,两组差异具有统计学意义,P<0.05。结论:晚期胃癌合并腹腔积液通过循环腹腔热灌注化疗可以提升治疗疗效,同时降低不良反应率,治疗疗效与安全性均有保证。
Objective: To investigate the adverse reactions of advanced gastric cancer combined with intraperitoneal hyperthermic perfusion chemotherapy. Methods: The patients with advanced gastric cancer complicated with ascites admitted to our hospital from October 2014 to October 2015 were divided into control group and observation group of 40 cases. The control group was treated with conventional chemotherapy. The observation group was given intraperitoneal hyperthermic perfusion Chemotherapy, analysis of two groups of patients with treatment and adverse reactions. Results: The effective rate of treatment was 80% in the observation group and 57.5% in the control group, with significant difference between the two groups (P <0.05). The incidence of adverse reactions was 45% in the observation group and 67.5% in the control group Group differences were statistically significant, P <0.05. Conclusion: Advanced gastric cancer combined with peritoneal effusion by intraperitoneal hyperthermic perfusion chemotherapy can improve the curative effect, reduce the rate of adverse reaction, and ensure the curative effect and safety.